VCEL - Vericel's Short Report: Deep Dive Into Knee-Repair Focused Company's 27 Years of Losses | Benzinga
J Capital Research has released a short idea report on Vericel Corporation (NASDAQ: VCEL), noting promising new applications for its cartilage-repair product yet consistently falling short on delivery.
Vericel specializes in manufacturing a substance known as MACI, designed to replace damaged cartilage in individuals with severe knee injuries.
Additionally, the company produces a burn treatment named Epicel, targeted at a very niche demographic—those who have suffered extensive burns covering at least 30% of their bodies.
The growth potential of these products is constrained. Cartilage surgery is ...